Flynn, who’s slated to start at Irvine, Calif.-based Biolase July 13, has headed up Zimmer Dental since 2007, Biolase said.
He replaces Jeffrey Nugent, who was brought in last year following the ouster of outspoken chief executive Federico Pignatelli as part of a contentious proxy war with Oracle Partners.
“Harold’s dental industry and medical device experience make him a natural fit to lead Biolase. He is a strategic thinker who has successfully managed global functions at Zimmer, much like he will do at Biolase. Harold has demonstrated an ability to build successful management teams, drive growth, and spur innovation at a number of companies, large and small. We are confident he is the right choice to continue the transformation of Biolase and we look forward to him joining the team,” chairman Paul Clark said in prepared remarks.
Clark added, “Jeff agreed as a Board member last summer to step in to help us, and I would like to thank him for the leadership and commitment he has shown in beginning the transformation of Biolase. He strengthened our leadership team and improved quality. We are grateful for his continued support and work with Biolase through the transition.”
“This is a very important and exciting time of transformation at Biolase. I look forward to helping Biolase achieve its considerable potential,” Flynn said. “With a demonstrated legacy of market-leading innovation providing patient-centric solutions and new laser-based treatment modalities, Biolase is well positioned to significantly expand its penetration and share in the markets it serves.”
Abbott promotes CFO Freyman, names Yoor as replacement
Abbott (NYSE:ABT) promoted CFO Thomas Freyman to executive vice president of finance & administration, naming investor relations vice president Brian Yoor as his replacement. Abbott also named John Capek executive vice president of ventures.
Reva Medical launches CEO search
Reva Medical (ASX:RVA) is looking for a new CEO to replace co-founder, chairman & CEO Robert Stockman, hoping to find someone with European and U.S. regulatory and commercialization experience. Stockman will stay on until the transition and remain chairman.
Google goes Mega with Baseline study
Google (NSDQ:GOOG) tapped a well-known cardiologist, Dr. Jessica Mega of Boston’s Brigham & Women’s Hospital and Harvard Medical School, for its Google X R&D arm. Mega will lead Google X’s Baseline big-data study.